苏拉明抑制兔后发性白内障的实验研究  

Experimental study of suramin preventing posterior capsule opacification

作　　者：卫芳[1] 周绍荣[1] 

机构地区：[1]上海第二医科大学附属仁济医院眼科,200001

出　　处：《中国眼耳鼻喉科杂志》2002年第6期339-342,T001,共5页Chinese Journal of Ophthalmology and Otorhinolaryngology

摘　　要：目的通过动物试验观察苏拉明对各组织是否具有毒性作用及对后囊膜混浊的防治作用,为该药应用于临床提供实验基础。方法选用新西兰白兔作角膜毒性实验和晶状体囊外摘除术,用不同浓度的苏拉明溶液进行囊袋内灌注,术后观察眼压,眼前段反应及后囊膜混浊情况。结果苏拉明可明显抑制后囊膜混浊的发生,对眼内组织无毒性作用。结论本实验证实了苏拉明囊袋内灌注的安全性和有效性,该药可能成为防治后囊膜混浊的新方向。Purpose We used suramin as an inhibitor. In vivo study we assessed its toxicity to ocular tissues and effect of preventing posterior capsule opacification(PCO) to estimate the validity and applicability in clinical procedure.Methods New Zealand albino rabbits were operated on for extracapsule cataract extraction(ECCE) and comeal toxicity experiment,infusing suramin of different concentration into the capsule bags following standard cataract surgery, to assess the incidence of PCO,comeal transparency, uveal reaporae and the change of introcular pressure. Results It is proved that suramin can prevent posterior capasule opacification without any toxicity to the ocular tissues. Conclusion In vivo experiment suramin shows its efficiency and safety after its infusion into the capasule bag, which suggests that suramin may become an applicable agent for PCO prevention.

关 键 词：苏拉明 抑制 后发性白内障 实验研究 治疗 

分 类 号：R776[医药卫生—眼科]